The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
-
Historical Article
Natural disasters, armed conflict, and public health.
-
Randomized Controlled Trial Multicenter Study
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was recently approved in the United States for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral agents. Dolutegravir, in combination with abacavir-lamivudine, may provide a simplified regimen. ⋯ Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine. (Funded by ViiV Healthcare; SINGLE ClinicalTrials.gov number, NCT01263015 .).